521 related articles for article (PubMed ID: 28350521)
1. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Kummar S; O'Sullivan Coyne G; Do KT; Turkbey B; Meltzer PS; Polley E; Choyke PL; Meehan R; Vilimas R; Horneffer Y; Juwara L; Lih A; Choudhary A; Mitchell SA; Helman LJ; Doroshow JH; Chen AP
J Clin Oncol; 2017 May; 35(14):1561-1569. PubMed ID: 28350521
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
Villalobos VM; Hall F; Jimeno A; Gore L; Kern K; Cesari R; Huang B; Schowinsky JT; Blatchford PJ; Hoffner B; Elias A; Messersmith W
Ann Surg Oncol; 2018 Mar; 25(3):768-775. PubMed ID: 28887726
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
Takahashi T; Prensner JR; Robson CD; Janeway KA; Weigel BJ
Pediatr Blood Cancer; 2020 Oct; 67(10):e28636. PubMed ID: 32762028
[TBL] [Abstract][Full Text] [Related]
4. Multifocal occurrence of extra-abdominal desmoid type fibromatosis - A rare manifestation. A clinicopathological study of 6 sporadic cases and 1 hereditary case.
Bekers EM; van Broekhoven DLM; van Dalen T; Bonenkamp JJ; van der Geest ICM; de Rooy JWJ; van Gorp JM; Creytens DH; de Leng WWJ; Scheijen B; Eijkelenboom A; Flucke U
Ann Diagn Pathol; 2018 Aug; 35():38-41. PubMed ID: 29705714
[TBL] [Abstract][Full Text] [Related]
5. Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases.
Chan D; Kaplan J; Gordon G; Desai J
Curr Oncol; 2021 Sep; 28(5):3659-3667. PubMed ID: 34590610
[TBL] [Abstract][Full Text] [Related]
6. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
Gounder M; Ratan R; Alcindor T; Schöffski P; van der Graaf WT; Wilky BA; Riedel RF; Lim A; Smith LM; Moody S; Attia S; Chawla S; D'Amato G; Federman N; Merriam P; Van Tine BA; Vincenzi B; Benson C; Bui NQ; Chugh R; Tinoco G; Charlson J; Dileo P; Hartner L; Lapeire L; Mazzeo F; Palmerini E; Reichardt P; Stacchiotti S; Bailey HH; Burgess MA; Cote GM; Davis LE; Deshpande H; Gelderblom H; Grignani G; Loggers E; Philip T; Pressey JG; Kummar S; Kasper B
N Engl J Med; 2023 Mar; 388(10):898-912. PubMed ID: 36884323
[TBL] [Abstract][Full Text] [Related]
7. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
[TBL] [Abstract][Full Text] [Related]
8. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
[TBL] [Abstract][Full Text] [Related]
9. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors).
Lips DJ; Barker N; Clevers H; Hennipman A
Eur J Surg Oncol; 2009 Jan; 35(1):3-10. PubMed ID: 18722078
[TBL] [Abstract][Full Text] [Related]
10. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
[TBL] [Abstract][Full Text] [Related]
11. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
Messersmith WA; Shapiro GI; Cleary JM; Jimeno A; Dasari A; Huang B; Shaik MN; Cesari R; Zheng X; Reynolds JM; English PA; McLachlan KR; Kern KA; LoRusso PM
Clin Cancer Res; 2015 Jan; 21(1):60-7. PubMed ID: 25231399
[TBL] [Abstract][Full Text] [Related]
12. CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm.
Wang WL; Nero C; Pappo A; Lev D; Lazar AJ; López-Terrada D
Pediatr Dev Pathol; 2012; 15(5):361-7. PubMed ID: 22372443
[TBL] [Abstract][Full Text] [Related]
13. Desmoid tumor: a disease opportune for molecular insights.
Kotiligam D; Lazar AJ; Pollock RE; Lev D
Histol Histopathol; 2008 Jan; 23(1):117-26. PubMed ID: 17952864
[TBL] [Abstract][Full Text] [Related]
14. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
[TBL] [Abstract][Full Text] [Related]
15. Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis.
Colombo C; Urbini M; Astolfi A; Collini P; Indio V; Belfiore A; Paielli N; Perrone F; Tarantino G; Palassini E; Fiore M; Pession A; Stacchiotti S; Pantaleo MA; Gronchi A
Genes Chromosomes Cancer; 2018 Oct; 57(10):495-503. PubMed ID: 29901254
[TBL] [Abstract][Full Text] [Related]
16. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.
Nathenson MJ; Hu J; Ratan R; Somaiah N; Hsu R; DeMaria PJ; Catoe HW; Pang A; Subhawong TK; Amini B; Sweet K; Feister K; Malik K; Jagannathan J; Braschi-Amirfarzan M; Sheren J; Caldas Y; Moreno Tellez C; Rosenberg AE; Lazar AJ; Maki RG; Benedetto P; Cohen J; Trent JC; Ravi V; Patel S; Wilky BA
Clin Cancer Res; 2022 Sep; 28(18):4092-4104. PubMed ID: 35180772
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
18. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
[TBL] [Abstract][Full Text] [Related]
19. Desmoid fibromatosis: MRI features of response to systemic therapy.
Sheth PJ; Del Moral S; Wilky BA; Trent JC; Cohen J; Rosenberg AE; Temple HT; Subhawong TK
Skeletal Radiol; 2016 Oct; 45(10):1365-73. PubMed ID: 27502790
[TBL] [Abstract][Full Text] [Related]
20. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis.
Gega M; Yanagi H; Yoshikawa R; Noda M; Ikeuchi H; Tsukamoto K; Oshima T; Fujiwara Y; Gondo N; Tamura K; Utsunomiya J; Hashimoto-Tamaoki T; Yamamura T
J Clin Oncol; 2006 Jan; 24(1):102-5. PubMed ID: 16382119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
